Transcode Therapeutics Business Summary

TransCode Therapeutics, Inc. (RNAZ) is a clinical-stage biopharmaceutical company specializing in RNA-based oncology therapeutics and diagnostics. The company operates as a pre-revenue entity, generating capital primarily through equity financing, federal research grants from the NIH and HHS, and strategic partnerships, including a $25 million investment from CK Life Sciences in late 2025 following the acquisition of Polynoma. Its business is segmented into its proprietary TTX nanoparticle delivery platform and a pipeline of therapeutic candidates, most notably its lead candidate TTX-MC138, which targets microRNA-10b to treat metastatic disease and is currently entering Phase 2a trials via a 2026 collaboration with Quantum Leap Healthcare Collaborative. TransCode competes in the specialized RNAi and antisense market against established players such as Arrowhead Pharmaceuticals, Ionis Pharmaceuticals, and Sirnaomics, positioning itself as a niche innovator focused on overcoming delivery barriers for RNA therapeutics in advanced solid tumors. The company was co-founded by Dr. Anna Moore, Dr. Zdravka Medarova, and Michael Dudley, leveraging foundational research from Harvard Medical School and Michigan State University. The current leadership team is headed by CEO and Chairman Dr. Philippe P. Calais, a biotech veteran with over 30 years of experience appointed in October 2025, and Thomas A. Fitzgerald, who serves as CFO and Director. Technical and clinical operations are led by Co-founder and Chief Technology Officer Dr. Zdravka Medarova, an expert in non-coding RNA, and Senior Development Officer Dr. Michel Janicot, who joined in late 2025. The company’s strategic oversight is bolstered by a board including recent appointee Jack E. Stover and institutional backing from CK Life Sciences and TRITON FUNDS.